SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
An acute leukemia with no evidence of myeloid differentiation by morphology and/or light microscopy cytochemistry. The myeloid nature of the blasts is demonstrated by immunological markers and/or ultrastructural cytochemistry.
This AML has little or no evidence of myeloid differentiation by morphology and light microscopy cytochemistry. The disease is identified by immunophenotyping and/or ultrastructural cytochemistry. Immunophenotyping is essential to distinguish this neoplasm from ALL.